摘要
作者从１６例肺癌患者手术切除的实体瘤及外周血中获得肿瘤浸润淋巴细胞（ＴＩＬ）和ＬＡＫ细胞，并对其体外抗肿瘤作用及其特异性应用￣３Ｈ－ＴｄＲ释放试验进行了测定。其中７例肺癌患者接受了ＴＩＬ回输过继免疫治疗，并于手术前及ＴＩＬ回输疗程结束时分别检测患者外周血Ｔ淋巴细胞亚群、ＮＫ细胞活性、可溶性白细胞介素－２受体及肝功、肾功、血象等。结果表明：在培养初期（３～５天），ＴＩＬ对自身肿瘤细胞的杀伤活性为２５．４±８．２，明显低于ＬＡＫ细胞的杀伤活性４２．８±１３．５（Ｐ＜０．０１）；在培养至２０～２５天时，ＴＩＬ的杀伤活性为５３．４±１１．２，明显高于ＬＡＫ细胞的杀伤活性３３．６±１２．７（Ｐ＜０．０１）。经ＴＩＬ回输的大部分患者一般状态明显改善，免疫功能增强。除有轻度发热及１例血压下降外，无其它明显副作用。病人的远期疗效正在随访观察中。
Abstract In 16 patients with lung
cancer tumor infiltrating iymphocytes(TIL)and peripheral
bloodlymphocytes(PBL)and their antitumor activities after IL-2
activation and were tested by￣3H-TdR releasing assay.The results
showed that the cytolytic activitly of TIL againstautologous tumor
cells was lower than of IL-2 activated PBL(LAK cells)at the
earlyincubation period but become markedly higher than that of LAK
cells when the incubation last-ed for 20 to 25 days.The subjectively
most patients received systemic TIL treatment felt betterand their
immune functions were improved.Transiant Low-grade fever occurred in
4 cases anddrop of arterial blood pressure in 1. No potentially fatal
toxic effect was observed.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1995年第2期152-155,共4页
Chinese Journal of Oncology
基金
吉林省科委科技基金
